Parents of children with autism launched an online petition urging the government and industry to help fund Seaside's work on a drug for autism and Fragile X syndrome. Roche Holding declined to exercise an option that would have provided funding after Seaside's experimental drug arbaclofen failed to meet clinical endpoints in a Phase IIb trial.

Full Story:

Related Summaries